Acoustic Cluster Therapy (ACT) enhances the therapeutic efficacy of paclitaxel and Abraxane® for treatment of human prostate adenocarcinoma in mice

• Published in: Journal of controlled release Vol. 236; pp. 15 - 21
• Main Authors: van Wamel, Annemieke, Sontum, Per Christian, Healey, Andrew, Kvåle, Svein, Bush, Nigel, Bamber, Jeffrey, de Lange Davies, Catharina
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 28.08.2016
• Subjects: Abraxane; Acoustic cluster therapy; Act; Albumin-Bound Paclitaxel - administration & dosage; Animals; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Cell Line, Tumor; Drug Delivery Systems; Drug Liberation; Humans; Male; Mice; Paclitaxel; Paclitaxel - administration & dosage; PC-3 prostate adenocarcinoma; Pre-clinical; Prostatic Neoplasms - drug therapy; Targeted drug delivery; Ultrasonic Waves; Pre-clinical; Targeted drug delivery; Acoustic cluster therapy; Act; Abraxane; PC-3 prostate adenocarcinoma; Paclitaxel
• ISSN: 0168-3659; 1873-4995
• DOI: 10.1016/j.jconrel.2016.06.018

Acoustic cluster therapy (ACT) is a novel approach for ultrasound mediated, targeted drug delivery. In the current study, we have investigated ACT in combination with paclitaxel and Abraxane® for treatment of a subcutaneous human prostate adenocarcinoma (PC3) in mice. In combination with paclitaxel (12mg/kg given i.p.), ACT induced a strong increase in therapeutic efficacy; 120days after study start, 42% of the animals were in stable, complete remission vs. 0% for the paclitaxel only group and the median survival was increased by 86%. In combination with Abraxane® (12mg paclitaxel/kg given i.v.), ACT induced a strong increase in the therapeutic efficacy; 60days after study start 100% of the animals were in stable, remission vs. 0% for the Abraxane® only group, 120days after study start 67% of the animals were in stable, complete remission vs. 0% for the Abraxane® only group. For the ACT+Abraxane group 100% of the animals were alive after 120days vs. 0% for the Abraxane® only group. Proof of concept for Acoustic Cluster Therapy has been demonstrated; ACT markedly increases the therapeutic efficacy of both paclitaxel and Abraxane® for treatment of human prostate adenocarcinoma in mice. [Display omitted]